The fusion gene BCR/ABL1 is present in 95% of CML patients and ~30% in ALL (acute lymphoblastic leukemia) and has been already precisely targeted and disrupted using the CRISPR/Cas system56. Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.